Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 20;14(1):4222.
doi: 10.1038/s41598-024-54516-9.

Primary results of the brazilian registry of atherothrombotic disease (NEAT)

Pedro G M de Barros E Silva  1   2   3   4 , Charlene Troiani do Nascimento  5 , Rodrigo Pinto Pedrosa  6 , Marcelo Arruda Nakazone  7 , Michel Ulloffo do Nascimento  5 , Leiliandry de Araújo Melo  6 , Osvaldo Lourenço Silva Júnior  8 , Sérgio Luiz Zimmermann  9 , Rodrigo Morel Vieira de Melo  10 , Ricardo Reinaldo Bergo  11 , Dalton Bertolim Precoma  12 , Lucas Tramujas  13 , Eduardo Gomes Lima  14 , João Miguel Malta Dantas  15 , Antônio Cláudio do Amaral Baruzzi  16   17 , Ronald Luiz Gomes Flumignan  18 , Maria Sanali Moura de Oliveira Paiva  19 , Luís Henrique Wolff Gowdak  14 , Priscila Nasser de Carvalho  20 , José Albuquerque de Figueiredo Neto  21 , Odilson Marcos Silvestre  22   23 , Alexandre Fioranelli  24 , Ricardo D 'Oliveira Vieira  25 , Ana Clara Peneluppi Horak  13 , Debora Harumi Kodama Miyada  13 , Flávia Cristina Soares Kojima  13 , Júlia Souza de Oliveira  13 , Leila de Oliveira Silva  13 , Ricardo Pavanello  13 , Eduardo Ramacciotti  24   26 , Renato D Lopes  27   28 ; NEAT Investigators
Collaborators, Affiliations

Primary results of the brazilian registry of atherothrombotic disease (NEAT)

Pedro G M de Barros E Silva et al. Sci Rep. .

Abstract

There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of patients with known coronary (CAD) and/or peripheral arterial disease (PAD) in Brazil. A total of 2,005 patients were enrolled among 25 sites from September 2020 to March 2022. Patient characteristics, medications and laboratorial data were collected. Primary objective was to assess the proportion of patients who, at the initial visit, were in accordance with good medical practices (domains) for reducing cardiovascular risk in atherothrombotic disease. From the total of patients enrolled, 2 were excluded since they did not meet eligibility criteria. Among the 2,003 subjects included in the analysis, 55.6% had isolated CAD, 28.7% exclusive PAD and 15.7% had both diagnoses. Overall mean age was 66.3 (± 10.5) years and 65.7% were male patients. Regarding evidence-based therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular dose of rivaroxaban (2.5 mg bid). Only 0.3% of the patients satisfied all the domains of secondary prevention, including prescription of EBTs and targets of body-mass index, blood pressure, LDL-cholesterol, and adherence of lifestyle recommendations. The main barrier for prescription of EBTs was medical judgement. Our findings highlight that the contemporary practice does not reflect a comprehensive approach for secondary prevention and had very low incorporation of new therapies in Brazil. Large-scale populational interventions addressing these gaps are warranted to improve the use of evidence-based therapies and reduce the burden of atherothrombotic disease.ClinicalTrials.gov NCT04677725.

Keywords: Cardiovascular diseases; Guideline adherence; Registries.

PubMed Disclaimer

Conflict of interest statement

PGMBS reports fees and research grants from Pfizer, Roche Diagnostics and Bayer. RDL reports research support from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer; Consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, Portola. All other co-authors report no conflicts of interest (conflict of interest: none declared).

Figures

Figure 1
Figure 1
Domains of cardiovascular prevention (medications, risk factor control and lifestyle habits).
Figure 2
Figure 2
Number of domains filled by patients in secondary prevention.
Figure 3
Figure 3
Main barriers to evidence-based therapies in the overall population.
See this image and copyright information in PMC

References

    1. Libby P. The interface of atherosclerosis and thrombosis: Basic mechanisms. Vasc. Med. 1998;3(3):225–229. doi: 10.1177/1358836X9800300309. - DOI - PubMed
    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498–1504. doi: 10.1016/S0140-6736(96)07492-2. - DOI - PubMed
    1. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The reduction of atherothrombosis for continued health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151(4):78 e6–10. doi: 10.1016/j.ahj.2005.11.004. - DOI - PubMed
    1. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW. REACH Registry Investigators International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189. doi: 10.1001/jama.295.2.180. - DOI - PubMed
    1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484. - DOI - PubMed

Associated data